Characteristics of patients at the time of diagnosis with secondary ITP or non-IT
| Characteristic . | Total . | Subgroup . | |||||
|---|---|---|---|---|---|---|---|
| Infection . | Autoimmunity . | Aplastic anemia . | Malignancy . | Immunodeficiency . | Drug-induced . | ||
| Total patients (%) | 113 (100) | 53 (100) | 42 (100) | 6 (100) | 7 (100) | 4 (100) | 1 |
| No. of patients with secondary ITP reported (%) | |||||||
| 6 mo | 73 (65) | 41 (77) | 19 (45) | 3 (50) | 6 (86) | 3 (75) | 1 |
| 12 mo | 20 (18) | 6 (11) | 13 (31) | 1 (17) | – | – | – |
| 24 mo | 20 (18) | 6 (11) | 10 (24) | 2 (3) | 1 (14) | 1 (25) | – |
| Age, median (IQR), y* | 7.3 (3.5;13.2) | 4.0† (2.3;7.2) | 13.4† (8.6;15.1) | 7.3 (5.4;10.6) | 3.5 (2.2;11.2) | 12.5 (6.3;14.6) | 14.3 |
| Platelet count, median (IQR), ×109/L | 163 (70;290) | 276† (163;336) | 86† (41;177) | 59 (33;72) | 142 (84;248) | 122 (91;150) | 290 |
| No. of patients with platelet count >100 × 109/L (%) | 71 (63) | 45 (85)† | 17 (40)† | 0 (0) | 5 (71) | 3 (75) | 1 |
| No. of patients with platelet count 20-100 × 109/L (%) | 32 (28) | 7 (13)† | 17 (40)† | 5 (83) | 2 (29) | 1 (25) | – |
| No. of patients with platelet count <20 × 109/L (%) | 10 (9) | 1 (1)† | 8 (19)† | 1 (17) | – | – | – |
| No bleeding (%)‡ | 77 (68) | 43 (81)§ | 25 (60)§ | 2 (33) | 3 (43) | 3 (75) | 1 |
| Platelet-enhancing treatment† | |||||||
| Total patients (%) | 40 (35) | 10 (19)† | 26 (62)† | 2 (33) | 1 (14) | 1 (25) | 0 |
| Second-line treatment|| | 18 (16) | 2 (4) | 15 (36) | 1 (17) | 0 | 0 | – |
| Characteristic . | Total . | Subgroup . | |||||
|---|---|---|---|---|---|---|---|
| Infection . | Autoimmunity . | Aplastic anemia . | Malignancy . | Immunodeficiency . | Drug-induced . | ||
| Total patients (%) | 113 (100) | 53 (100) | 42 (100) | 6 (100) | 7 (100) | 4 (100) | 1 |
| No. of patients with secondary ITP reported (%) | |||||||
| 6 mo | 73 (65) | 41 (77) | 19 (45) | 3 (50) | 6 (86) | 3 (75) | 1 |
| 12 mo | 20 (18) | 6 (11) | 13 (31) | 1 (17) | – | – | – |
| 24 mo | 20 (18) | 6 (11) | 10 (24) | 2 (3) | 1 (14) | 1 (25) | – |
| Age, median (IQR), y* | 7.3 (3.5;13.2) | 4.0† (2.3;7.2) | 13.4† (8.6;15.1) | 7.3 (5.4;10.6) | 3.5 (2.2;11.2) | 12.5 (6.3;14.6) | 14.3 |
| Platelet count, median (IQR), ×109/L | 163 (70;290) | 276† (163;336) | 86† (41;177) | 59 (33;72) | 142 (84;248) | 122 (91;150) | 290 |
| No. of patients with platelet count >100 × 109/L (%) | 71 (63) | 45 (85)† | 17 (40)† | 0 (0) | 5 (71) | 3 (75) | 1 |
| No. of patients with platelet count 20-100 × 109/L (%) | 32 (28) | 7 (13)† | 17 (40)† | 5 (83) | 2 (29) | 1 (25) | – |
| No. of patients with platelet count <20 × 109/L (%) | 10 (9) | 1 (1)† | 8 (19)† | 1 (17) | – | – | – |
| No bleeding (%)‡ | 77 (68) | 43 (81)§ | 25 (60)§ | 2 (33) | 3 (43) | 3 (75) | 1 |
| Platelet-enhancing treatment† | |||||||
| Total patients (%) | 40 (35) | 10 (19)† | 26 (62)† | 2 (33) | 1 (14) | 1 (25) | 0 |
| Second-line treatment|| | 18 (16) | 2 (4) | 15 (36) | 1 (17) | 0 | 0 | – |
% refers to the total number of patients in the subgroups.
At follow-up reporting “secondary ITP or non-IT.”
Between the subgroups infection-associated and autoimmune-associated ITP, P < .001.
In the period of time between 2 time points (0-6 months, 6-12 months, or 12-24 months).
Between the subgroups infection-associated and autoimmune-associated ITP, P < .05.
Second-line treatment: drugs other than corticosteroids, anti-D immunoglobulin, or IVIG.